🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the fight against superbug strains of the pathogen, according to health experts.

An International Health Concern

Gonorrhoea infections are on the rise around the world, with estimates suggesting more than 82 million new cases each year. Especially elevated rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary step in the face of rising global incidence, the spread of superbugs and the very limited therapeutic options presently on offer.”

Public health authorities are deeply concerned about the rise in treatment-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Gain Approval

Zoliflodacin, alternatively called a brand name, was authorized by the US Food and Drug Administration in December for treating gonorrhoea. This disease can lead to major issues, including infertility. Experts anticipate that specific application of this new drug will help delay the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This authorization represents a major breakthrough in the management of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Results and Worldwide Availability

According to results released by a prominent scientific publication, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which combines a dual-drug approach. The study involved over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the rights to register and commercialise the drug in a wide range of developing nations.

Doctors on the front lines have voiced optimism. The availability of a easy-to-administer therapy like this is described as a "revolutionary step" for gonorrhoea control. This is deemed essential to reduce the burden of the illness for people and to prevent the spread of highly drug-resistant gonorrhoea around the world.